Frontlight ResearchEarly access
Active, not recruitingPhase 2
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Key facts
- Who runs it
- Neurocrine Switzerland GmbH
- Where
- Germany3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 7 people enrolled
- Started
- 30 Sept 2025
- Expected to end
- 4 Oct 2029
- Type of study
- Interventional
- Treatments tested
- Crinecerfont
- Record updated
- 28 August 2026
Who can take part
- Age
- 0 years to 23 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Be a female or male between 0 to <2 years of age at screening
- Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency (21-OHD)
- Be on a clinically stable regimen of hydrocortisone (and fludrocortisone, if applicable) treatment
Who cannot take part
- Have any condition besides CAH that requires chronic daily therapy with orally administered steroids
- Have any other clinically significant medical condition or chronic disease; Note: Other protocol-defined inclusion and exclusion criteria may apply
- Have a known or suspected diagnosis of any of the other forms of classic CAH
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to <2 years of age with congenital adrenal hyperplasia (CAH).
The group in the trial
- CrinecerfontTreatment being tested
Participants with CAH will receive crinecerfont during an initial 14-day treatment period, followed by an optional 36-month open-label extension (OLE).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
- Record updated
- 28 August 2026